While the reviewed MR studies indicate that CXCL10 inhibition and LRRTM2 modulation are genetically linked to SGLT2 inhibitor benefits in HF, these findings must be validated through direct experimental models. This evidence concerns the gene SLC5A2 and hydrops fetalis.